Bad idea [Two-Stage / GS Designs]

posted by Helmut Homepage – Vienna, Austria, 2013-10-19 17:04 (4619 d 11:12 ago) – Posting: # 11710
Views: 29,822

Hi Kumar,

❝ We have already included Potvin's method C in our statistical analysis plan in the protocol. According to our client we should change our design to normal 2x2 crossover design.


The study’s power will drop – in some cases substantially – which may render the study unethical. I hope the study was planned in such a way, that the sample size in stage 1 was large enough to show BE if the assumption about the CV turns out to be correct (that’s the idea behind Method C). If the sponsor played Bingo (“We guess that the CV will be 20%, but maybe we will pass with only 16 – or even 12 – sub­jects. Let’s try.”) you will be in trouble if you switch to a conventional 2×2 design.
Example (T/R 95%, CV 20%, target power 80%): The sample size in a conventional 2×2 cross-over will be 20 (power 83.5%). If you perform the study in 16 subjects, power will be 73.5% (unethical). With only 12 power will be 56.6% (crazy). Compare this to Method C (106 simulations, exact* power estimation):
  1. Stage 1 sample size 20:
    Overall power 86.3%, power in stage 1 75.1%.
    Average total sample size 22 (n5% 20, median 20, n95% 32, nmax 64).
    18.7% of studies proceed to the second stage.
  2. Stage 1 sample size 16:
    Overall power 85.2%, power in stage 1 61.9%.
    Average total sample size 20 (n5% 16, median 16, n95% 36, nmax 80).
    34.1% of studies proceed to the second stage.
  3. Stage 1 sample size 12:
    Overall power 84.0%, power in stage 1 41.2%.
    Average total sample size 21 (n5% 12, median 18, n95% 40, nmax 98).
    56.5% of studies proceed to the second stage.
In scenario I (stage 1 sample size = fixed design sample size) you have a fairly high chance (75.1%) to show BE already in the first stage; only 18.7% chance to proceed to the second stage. Note that power in the first stage (75.1%) is lower than in a fixed sample design (83.5%) because in some studies you have to use the wider 94.12% CI ⇒ less likely to pass than with the conventional 90% CI.
In scenario II (= gambling) the chance to show BE in the first stage is only 61.9%; chance to proceed to the second stage is 34.1%. Note the distribution of total sample sizes – a consequence of the penalty.
Let’s be silent about scenario III.

❝ Now the problem is we have dosed volunteers and I think CRO has started bioanalyis part (but not statistical analysis). In this situation can we ammend the protocol or we need to repeat the study with ammended protocol.


I would do neither; as shown above power may drop – ethical problems. If the sponsor is wary about EMA’s acceptance of Method C, consider switching to Method B instead.
Can you post your assumed CV and stage 1 sample size?



Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,571 registered users;
109 visitors (0 registered, 109 guests [including 17 identified bots]).
Forum time: 04:17 CEST (Europe/Vienna)

To propose that poor design can be corrected by subtle analysis techniques
is contrary to good scientific thinking.    Stuart J. Pocock

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5